Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tabelecleucel + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Atara Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
Tabelecleucel + pembrolizumab is an investigational combination therapy being studied primarily for platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated nasopharyngeal carcinoma (EBV+ NPC). Tabelecleucel is an allogeneic, off-the-shelf EBV-specific cytotoxic T-cell immunotherapy designed to target and eliminate EBV-infected cells. It is administered intravenously and is selected from a donor bank based on human leukocyte antigen (HLA) matching. Pembrolizumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with ligands and facilitating T-cell–mediated anti-tumor immune responses. The combination aims to enhance anti-tumor efficacy by leveraging direct cytotoxic elimination of EBV-positive cells (tabelecleucel) and releasing T-cell inhibition (pembrolizumab)[1][2][5][6].
- Other names
- tab-cel + pembrolizumab
02
Targets
pMHC-I (Peptide–MHC class I complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tabelecleucel + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tabelecleucel + pembrolizumab.